Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Cell Lymphoma

Regimen is approved for frontline treatment, but when it represents the best choice is less clear

Related Keywords

Philadelphia ,Pennsylvania ,United States ,Tampa ,Florida ,Delaware ,Leah Lawrence ,Jakub Svoboda ,Michael Jain ,Moffitt Cancer Center ,National Comprehensive Cancer Network ,Penn Medicine ,B Cell Lymphoma ,Diffuse Largeb Cell Lymphoma ,Vincristine ,Neuropathy ,Rituximab ,